Scientists develop potential single-dose breast cancer treatment

Researchers at the University of Illinois at Urbana-Champaign (UIUC) have announced a promising breakthrough in the treatment of estrogen receptor-positive breast cancer.

A single dose of a synthetic molecule, named ErSO-TFPy, has demonstrated the ability to completely eradicate small breast tumors and significantly shrink larger ones in mouse models.

This novel treatment has the potential to revolutionise breast cancer care, offering a less invasive and more effective alternative to current therapies. Estrogen receptor-positive breast cancer accounts for approximately 70% of all breast cancer cases, making this discovery particularly impactful.

Professor Paul Hergenrother, who led the study, emphasised the rarity of such results. "It is very unusual for a compound to not only shrink tumors in mouse models but to completely eliminate them with just one dose," he said in a statement.

Currently, patients with estrogen receptor-positive breast cancer undergo surgery followed by years of adjuvant hormone therapy. While effective, this prolonged treatment can significantly impact quality of life, causing side effects such as blood clots, musculoskeletal pain, sexual dysfunction, and fatigue.

The research team highlighted the potential of their findings, stating, "An anti-cancer regimen involving a single dose or just a few doses could transform breast cancer treatment."

While further studies and clinical trials are needed to confirm the efficacy and safety of ErSO-TFPy in humans, the results offer hope for a less burdensome and more efficient treatment for millions of breast cancer patients worldwide.